ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/24/20

Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time. The call had previously been scheduled for 8:00 a.m. ET. All other aspects of the call remain unchang...

Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...

For investors, 2019 was the sort of year that dreams are made of. When the curtain finally closed, the benchmark S&P 500 had gained nearly 32%, inclusive of dividends paid, which is well over four times the historic average annual return of the index of 7%, inclusive of dividends and when ...

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020. Following the release of the financial results, Alexion manage...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this Read more ...

Alexion Pharmaceuticals ( ALXN -2% ) plans to launch a late-stage study, CHAMPION-ALS, this quarter evaluating Ultomiris (ravulizumab-cwvz) in patients with amyotrophic lateral sclerosis (ALS). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...

- 50-week global study to enroll ~350 patients across broad ALS population - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS ® (ravulizumab) in amyotrophic lateral sclerosis (ALS). The 50-week global stu...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...